Cost-effectiveness analysis of revisional Roux-en-Y gastric bypass: laparoscopic vs. robot assisted.


Journal

Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 02 08 2022
accepted: 14 11 2022
pubmed: 25 11 2022
medline: 14 1 2023
entrez: 24 11 2022
Statut: ppublish

Résumé

There is controversy over the possible advantages of the robotic technology in revisional bariatric surgery. The aim of this study is to report the experience of a high-volume bariatric center on revisional Roux-en-Y gastric bypass with robot-assisted (R-rRYGB) and laparoscopic (L-rRYGB) approaches, with regards to operative outcomes and costs. Patients who underwent R-rRYGB and L-rRYGB between 2008 and 2021 were included. Patients' baseline characteristics and perioperative data were recorded. The primary endpoint was the overall postoperative morbidity. A full economic evaluation was performed. One-way and two-way sensitivity analyses were performed on laparoscopic anastomotic leak and reoperation rates. A total of 194 patients were included: 44 (22.7%) L-rRYGB and 150 (77.3%) R-rRYGB. The robotic approach was associated with lower overall complication rate (10% vs. 22.7%, p = 0.038), longer operative time, and a reduced length of stay compared to L-rRYGB. R-rRYGB was more expensive than L-rRYGB (mean difference 2401.1€, p < 0.001). The incremental cost-effective ratio (ICER) was 18,906.3€/complication and the incremental cost-utility ratio was 48,022.0€/QALY (quality-adjusted life years), that is below the willingness-to-pay threshold. Decision tree analysis showed that L-rRYGB was the most cost-effective strategy in the base-case scenario; a probability of leak ≥ 13%, or a probability of reoperation ≥ 14% following L-rRYGB, or a 12.7% reduction in robotic costs would be required for R-rRYGB to become the most cost-effective strategy. R-rRYGB was associated with higher costs than L-rRYGB in our base-case scenario. However, it is an acceptable alternative from a cost-effectiveness perspective.

Identifiants

pubmed: 36422812
doi: 10.1007/s13304-022-01425-z
pii: 10.1007/s13304-022-01425-z
pmc: PMC9834166
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

189-196

Informations de copyright

© 2022. The Author(s).

Références

Surg Obes Relat Dis. 2020 Mar;16(3):397-405
pubmed: 31932204
Am J Manag Care. 2010 Jul 01;16(7):e174-87
pubmed: 20645663
Ann Surg. 2016 Nov;264(5):871-877
pubmed: 27429035
Surg Endosc. 2014 Feb;28(2):414-26
pubmed: 24196545
Obes Surg. 2020 Jan;30(1):11-17
pubmed: 31372875
Chirurgia (Bucur). 2021 Jan-Feb;116(1):7-15
pubmed: 33638321
Obes Surg. 2012 Jan;22(1):52-61
pubmed: 21538177
Obes Surg. 2015 Nov;25(11):2180-9
pubmed: 26344797
Pharmacoeconomics. 2008;26(9):733-44
pubmed: 18767894
Surg Endosc. 2021 Aug;35(8):4200-4205
pubmed: 32857240
Obes Surg. 2018 Jul;28(7):2083-2091
pubmed: 29748735
Value Health. 2013 Mar-Apr;16(2):e1-5
pubmed: 23538200
Obes Surg. 2018 Nov;28(11):3691-3700
pubmed: 30178157
Obes Surg. 2021 Nov;31(11):5022-5033
pubmed: 34410582
Obes Surg. 2015 Jul;25(7):1271-80
pubmed: 25893649
Int J Med Robot. 2014 Jun;10(2):213-7
pubmed: 24167029
Cent Eur J Oper Res. 2018;26(1):135-159
pubmed: 29375266
Obes Surg. 2021 Apr;31(4):1656-1663
pubmed: 33392998
Visc Med. 2020 Jun;36(3):238-245
pubmed: 32775356
Surg Obes Relat Dis. 2014 Sep-Oct;10(5):952-72
pubmed: 24776071
Int J Med Robot. 2011 Dec;7(4):393-400
pubmed: 22113976
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Obes Surg. 2016 Dec;26(12):3031-3044
pubmed: 27726045
Obes Surg. 2018 Jul;28(7):1852-1859
pubmed: 29417487

Auteurs

Elettra Ugliono (E)

Department of Surgical Sciences, University of Turin, Corso A.M. Dogliotti 14, 10126, Turin, Italy. elettra.ugliono@unito.it.
Department of Mechanical and Aerospacial Engineering, Politecnico of Turin, Corso Duca Degli Abruzzi 24, 10129, Turin, Italy. elettra.ugliono@unito.it.

Fabrizio Rebecchi (F)

Department of Surgical Sciences, University of Turin, Corso A.M. Dogliotti 14, 10126, Turin, Italy.

Costanza Vicentini (C)

Department of Public Health and Pediatrics, University of Turin, Via Santena 5 Bis, 10126, Turin, Italy.

Antonio Salzano (A)

Department of Surgical Sciences, University of Turin, Corso A.M. Dogliotti 14, 10126, Turin, Italy.

Mario Morino (M)

Department of Surgical Sciences, University of Turin, Corso A.M. Dogliotti 14, 10126, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH